Choosing a course is one of the most important decisions you'll ever make! View our courses and see what our students and lecturers have to say about the courses you are interested in at the links below.
Each year more than 4,000 choose NUI Galway as their University of choice. Find out what life at NUI Galway is all about here.
About NUI Galway
About NUI Galway
Since 1845, NUI Galway has been sharing the highest quality teaching and research with Ireland and the world. Find out what makes our University so special – from our distinguished history to the latest news and campus developments.
Colleges & Schools
Colleges & Schools
NUI Galway has earned international recognition as a research-led university with a commitment to top quality teaching across a rang of key areas of expertise.
Business & Industry
Guiding Breakthrough Research at NUI Galway
We explore and facilitate commercial opportunities for the research community at NUI Galway, as well as facilitating industry partnership.
- Alumni, Friends & Supporters
At NUI Galway, we believe that the best learning takes place when you apply what you learn in a real world context. That's why many of our courses include work placements or community projects.
Prof Michael O'Dwyer MB, BCH, BAO (Hons) MRCPI, MRCPATH
Peer Reviewed Journals
|O'Dwyer, M,Atallah, E (2009) 'Practical Considerations for the Management of Patients in the Tyrosine Kinase Inhibitor Era'. Seminars In Hematology, 46 :16-21. [DOI] [Details]|
|Meenaghan T, O'Dwyer M, Hayden P, Hayat A, Murray M, Dowling M. Home (2010) 'administration of bortezomib: making a difference to myeloma patients' lives. Eur'. J Oncol Nurs, 14 (2):134-136. [Details]|
|Swords R, Mahalingam D, O'Dwyer M, Santocanale C, Kelly K, Carew J, Giles F. (2010) 'Cdc7 kinase - a new target for drug development'. Eur J Cancer, 46 (1):33-40. [Details]|
|Krawczyk J, Ansar N, Swords R, Murphy T, MacDonagh B, Meenaghan T, Hayden P,Hayad A, Murray M, O'Dwyer M. (2010) 'Clofarabine in the treatment of poor risk acute myeloid leukaemia'. Hematol Oncol, 28 (3):118-123. [DOI] [Details]|
|Cronin CG, Swords R, Truong MT, Viswanathan C, Rohren E, Giles FJ, O'Dwyer M, (2010) 'Bruzzi JF. Clinical utility of PET/CT in lymphoma. AJR Am J Roentgenol. 2010'. Review, 191 (1):W91-W103. [DOI] [Details]|
|Swords RT, Kelly KR, Smith PG, Garnsey JJ, Mahalingam D, Medina E, Oberheu K,Padmanabhan S, O'Dwyer M, Nawrocki ST, Giles FJ, Carew JS (2010) 'Inhibition of EDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia'. Blood, 115 (18):3796-3800. [DOI] [Details]|
|Van Dijk M, Murphy E, Morrell R, Knapper S, O'Dwyer M, Samali A and Szegezdi E. (2011) 'The Proteasome Inhibitor Bortezomib Sensitizes AML with Myelomonocytic'. Differentiation to TRAIL Mediated Apoptosis Cancers, 3 (1):1329-1350. [DOI] [Details]|
|McCarron SL, Kelly J, Coen N, McCabe S, Fay M, O'Dwyer M, Hayden PJ, Langabeer (2011) 'SE. A novel e8a2 BCR-ABL1 fusion with insertion of RALGPS1 exon 8 in a patient with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia'. Leuk Lymphoma, 52 (5):919-921. [Details]|
|O'Dwyer, MC,Kent, E,Parker, M,Swords, RT,Giles, F,le Coutre, P,Padmanabhan, S,Moulton, B,McMullin, MF,Langabeer, S,Egan, K,Conneally, E (2009) Nilotinib 300 Mg Twice Daily Is Effective and Well Tolerated as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia in Chronic Phase: Preliminary Results of the ICORG 0802 Phase 2 Study. Abstract [Details]|